AcquisitionsJul 29, 2026, 05:27 PM
J&J updates 2026 EPS guidance after Firefly acquisition, Sail deal
AI Summary
Johnson & Johnson announced the completion of its acquisition of Firefly Bio, Inc. for $1 billion and entered into strategic agreements and collaboration with Sail Biomedicines, including a $465 million equity investment and an exclusive option to acquire Sail for $2.58 billion. These transactions are expected to reduce the company's 2026 Adjusted Operational EPS and Adjusted EPS by approximately $0.64, and by approximately $1.36 in 2027. As a result, J&J updated its full-year 2026 guidance, lowering the Adjusted Operational EPS midpoint from $11.58 to $10.94 and Adjusted EPS midpoint from $11.68 to $11.04.
Key Highlights
- Acquisition of Firefly Bio completed for $1 billion in cash.
- Strategic agreements and collaboration entered with Sail Biomedicines.
- J&J made a $465 million equity investment in Sail Biomedicines.
- J&J granted an exclusive option to acquire Sail for $2.58 billion.
- Combined transactions to reduce 2026 Adjusted EPS by approximately $0.64.
- Combined transactions to reduce 2027 Adjusted EPS by approximately $1.36.
- Updated 2026 Adjusted Operational EPS guidance midpoint lowered to $10.94.
- Updated 2026 Adjusted EPS guidance midpoint lowered to $11.04.
Price Impact
More from JNJ